7th Feb 2019 07:00
7 February 2019
Cello Health plc
("Cello" or the "Group")
Notice of Full Year Results
Cello Health plc (AIM: CLL), the healthcare-led advisory group, expects to announce its preliminary results for the year ended 31 December 2018 on Thursday 21 March 2019.
A meeting for analysts will be held at 10.00am on the morning of the results announcement at the offices of Buchanan, 107 Cheapside, London EC2V 6DN. For further details please contact Buchanan on 020 7466 5000 or email [email protected].
Enquiries:
Cello Health plc | 020 7812 8460 |
Mark Scott, Chief Executive | |
Mark Bentley, Group Finance Director | |
Cenkos Securities (Nominated adviser and broker) | 020 7397 8900 |
Mark Connelly | |
Harry Hargreaves | |
Buchanan | 020 7466 5000 |
Mark Court | |
Jamie Hooper | |
Sophie Wills |
About Cello Health plc
Cello Health plc is a global healthcare-focused advisory Group comprised of a set of leading clinical, commercial advisory and digital delivery capabilities. Cello Health plc currently services 24 of the top 25 pharmaceutical clients globally, as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients.
Cello Health plc enables clients to commercialise and differentiate their assets and drive brand success in ever more complex global markets. The business delivers its services through nearly 1,000 highly skilled professionals, utilising latest thinking, technology and digital solutions.
Cello Health plc delivers its services from an office network in the UK, USA, and Asia, with hub offices in New York City, Philadelphia PA, London, Edinburgh, Farnham and Cheltenham.
For further information, please visit: https://cellohealthplc.com
Related Shares:
CLL.L